目的 探討膽香鼻炎片聯(lián)合糠酸莫米松治療過(guò)敏性鼻炎的安全性與有效性。方法 選取2019年12月—2020年12月在平煤神馬集團(tuán)總醫(yī)院診治的121例過(guò)敏性鼻炎患者，按照入組順序分成對(duì)照組（61例）和治療組（60例）。對(duì)照組患者采用糠酸莫米松鼻噴霧劑噴鼻治療，2撳/次，1次/d，待癥狀有效控制后藥量改為1撳/次，1次/d；治療組在對(duì)照組患者基礎(chǔ)上口服膽香鼻炎片，4片/次，3次/d。兩組患者連續(xù)治療6周。觀察兩組患者臨床療效，比較治療前后兩組患者RQLQ評(píng)分和癥狀評(píng)分，血清白細(xì)胞介素-6（IL-6）、白細(xì)胞介素-27（IL-27）和γ干擾素（IFN-γ）水平及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組臨床有效率為81.97%，明顯低于治療組的95.00%（P<0.05）；治療后，兩組患者RQLQ評(píng)分和癥狀評(píng)分均較治療前顯著降低（P<0.05），且治療組降低更顯著（P<0.05）；治療后，兩組患者血清IL-6、IFN-γ水平顯著降低，而IL-27顯著升高（P<0.05），且治療組比對(duì)照組改善更顯著（P<0.05）。治療期間，對(duì)照組不良反應(yīng)發(fā)生率明顯高于治療組（19.67%vs 5.00%，P<0.05）。結(jié)論 膽香鼻炎片聯(lián)合糠酸莫米松鼻噴霧劑治療過(guò)敏性鼻炎療效確切，可顯著改善患者臨床癥狀和生存質(zhì)量，且不良反應(yīng)發(fā)生率低。

Objective To explore the safety and efficacy of Danxiang Biyan Tablets combined with mometasone furoate in treatment of allergic rhinitis. Methods Patients (121 cases) with allergic rhinitis in General Hospital of Pingmei Shenma Group from December 2019 to December 2020 were divided into control (61 cases) and treatment (60 cases) groups according to the grouping order. Patients in the control group were administered with Mometasone Furoate Aqueous Nasal Spray, 2 press/time, once daily. Patients in the treatment group were po administered with Danxiang Biyan Tablets, 4 tablets/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, the RQLQ scores, symptom scores, the serum IL-6, IL-27 and IFN-γ levels, the adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the control group was 81.97%, which was significantly lower than 95.00% of the treatment group (P < 0.05). After treatment, the RQLQ score and symptom score in two groups were significantly lower than those before treatment (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the levels of serum IL-6 and IFN-γ in two groups were significantly decreased, while the level of IL-27 were significantly increased (P < 0.05), and the treatment group improved more significantly than the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the control group was significantly higher than that in the treatment group (19.67% vs 5.00%, P < 0.05). Conclusion Danxiang Biyan Tablets combined with mometasone furoate is effective in treatment of allergic rhinitis which can significantly improve the clinical symptoms and quality of life, and the incidence of adverse reactions is low.

R987

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（152102310047）